In a landmark global health decision announced at the European Congress of Endocrinology in Prague, Polycystic Ovary Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) after a 14-year consultation involving medical experts, researchers and patient advocacy groups across six continents. Published in The Lancet, the change aims to correct decades of misunderstanding around the condition, which affects more than 170 million women globally.
Experts said the previous name inaccurately focused on ovarian cysts, despite the disorder also impacting hormonal balance, metabolism, fertility, cardiovascular health and mental wellbeing. Researchers and patient groups have welcomed the move, saying it could improve diagnosis, reduce stigma and encourage more holistic treatment approaches, with the full transition expected to be incorporated into international medical guidelines by 2028.
Why The Name Change Matters For Millions
The renaming process was spearheaded by Helena Teede, director of the Monash Centre for Health Research and Implementation in Australia, who said the earlier term “PCOS” failed to capture the “multi-system burden” faced by patients. According to experts involved in the consultation, many women experienced delayed diagnosis or fragmented treatment because the condition was largely viewed as a reproductive disorder linked to ovarian cysts, even though many patients never develop cysts at all.
The newly adopted term PMOS – Polyendocrine Metabolic Ovarian Syndrome is intended to reflect the condition’s broader endocrine and metabolic dimensions. Medical researchers noted that PMOS can affect insulin regulation, weight, skin health, mental health and fertility, while also increasing the risk of type 2 diabetes, cardiovascular disease and anxiety or depression. Reports suggest that more than 50 global organisations, including patient-led groups, participated in the consultation process, making it one of the most extensive naming reforms in women’s healthcare in recent years.
According to the World Health Organization’s PCOS fact sheet, the condition affects nearly 10–13% of women of reproductive age globally, with up to 70% remaining undiagnosed. Common symptoms include irregular periods, acne, excess facial hair, infertility, weight fluctuations and hair thinning.
Global Experts And Patients
The announcement was formally made during the 2026 European Congress of Endocrinology in Prague and simultaneously published in The Lancet, signalling broad scientific consensus behind the decision. Experts said the previous terminology often trivialised the disorder and reinforced misconceptions that it was solely a gynaecological issue. Researchers also highlighted cultural concerns, particularly in conservative societies where reproductive health labels may contribute to stigma or discourage women from seeking medical support.
Patient advocates involved in the process described the renaming as emotionally significant. Several women living with PMOS reportedly shared experiences of years-long diagnostic confusion, body-image struggles and mental health challenges linked to the condition. Advocacy groups argued that a medically accurate name could improve public understanding and encourage healthcare systems to adopt more integrated treatment models instead of focusing only on fertility-related symptoms.
Health experts further clarified that while the name is changing, existing treatments and diagnostic frameworks will continue during the transition period. Current management strategies include lifestyle interventions, hormonal therapy, insulin-sensitising medicines such as Metformin and fertility support where required. The revised terminology is expected to be gradually integrated into international classification systems and updated clinical guidelines by 2028.
The Logical Indian’s Perspective
The renaming of PCOS to PMOS is more than a scientific update, it reflects a growing recognition that women’s health conditions deserve accurate representation, deeper research and compassionate care. For years, millions of women have struggled not only with symptoms but also with misunderstanding, stigma and delayed diagnoses rooted partly in inadequate medical language. A name that better reflects the condition’s hormonal, metabolic and psychological impact could help shift public conversation from silence and shame towards awareness and support.
However, terminology alone cannot solve systemic gaps in healthcare. Governments, medical institutions and educators must ensure that awareness campaigns, affordable diagnosis and long-term treatment reach women across socio-economic backgrounds, especially in countries where reproductive and mental health discussions remain taboo. As science evolves, healthcare systems must evolve with empathy too. Could this global shift in medical language become the starting point for more inclusive and holistic women’s healthcare worldwide?
Also Read: Eli Lilly Tried To Start An Obesity Conversation, Regulators Heard A Sales Pitch
PCOS is renamed PMOS, Lancet-backed change follows 14-year global campaign
— Corax (@coraxnews) May 12, 2026
A condition defined by metabolism stops being branded as cystshttps://t.co/HyG9YQG7Cu
A global coalition of medical societies and patient groups has agreed to rename polycystic ovary syndrome (PCOS) as…
